TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of patients with progression of thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maternal Erythroferrone During Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maternal Erythroferrone at Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neonatal Erythroferrone at Birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Placental Erythroferrone mRNA and Ferroportin protein Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Sequential Organ Failure Assessment (SOFA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death Within 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: Admission to an Intensive Care Unit (ICU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Use of Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood Pressure Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oral health status measured by caries index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Become Syncopal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of chemotherapy interruptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Efficacy subscale of the Parenting Sense of Competence Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urinary Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sustained Parasitological Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Cobalamin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving Sustained Virologic Response at 24 Weeks Following Treatment Completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid Level at Week 24 and Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With At Least a 2log10 Drop in Hepatitis C Virus Ribonucleic Acid at Week 24 as Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reoperation rates following WLE or IORT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Vaginal or Urinary Symptoms After Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the concentration-time Curve (AUC) from zero to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability measured by nature, frequency and severity of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 24
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 24
Endpoint domain: Adverse events/effects
Primary endpoint: Change in renal function as measured by eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hepatitis C viral load (RNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factor VIII inhibitor development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Conversion to negative rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability of Compound GW506U78
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Compound GW506U78
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of repeat suicide attempts
Endpoint domain: Mortality/survival
Primary endpoint: Tuberculosis prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Tinnitus Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: death up to discharge of hospital
Endpoint domain: Mortality/survival
Primary endpoint: combined death up to discharge and severe white matter injury
Endpoint domain: Mortality/survival
Primary endpoint: PTSD Checklist (PCL) Slope
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 15-Item Word List Delayed Recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Variability of mitoPO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural control of respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Return to Continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of exposure to central venous catheter
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Turn Protocol Compliance
Endpoint domain: Adverse events/effects
Primary endpoint: Denture area covered with biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum electrolytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RNA expression on platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: allelic DNA balance of EVs in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the first dose of rescue analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Physical Component Summary Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility measured by the number of weekly sessions attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quick Inventory of Depressive Symptomatology (QIDS-SR 16)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feeding Behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to remain stable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of left ventricular end-diastolic volume index (LVEDVi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity, specificity, and predictive value of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful surgical completeness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recurrence rate of thyroid cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Successful ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Infant fecal B. infantis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Infant fecal Bifidobacterium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Infant fecal total bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Infant fecal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Infant gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Infant health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax and AUClast of Telmisartan/Amlodipine/Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute and late adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Post-injection Serum Cortisol Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Child absolute change in BMI Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of sleep efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: NIPS score during heel prick
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta of Apnea Hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline Late-Life Function and Disability Instrument
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rectal emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rectoanal pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Referral rates for hearing evaluation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety endpoints
Endpoint domain: Adverse events/effects
Primary endpoint: ADHD-Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of completers
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of feeding tube dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in thigh subcutaneous adipose tissue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Percent Change From Baseline in the Papules and Pustules Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Difference in immune cell profile in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in cytokine production of mononuclear cells to fungal stimulation in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in function of blood neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful Implant Delivery (30d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Treatment Success (1year)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Circumference Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Confirmed FVIII Inhibitor Development
Endpoint domain: Adverse events/effects
Primary endpoint: Length of stay in days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Scores on general psychiatric rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on violent or threatening incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Failure free survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of eligible patients who received the mobile team exam
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: beta-index dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of asthmatic patients who are CF carriers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of cognitive assessment administration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intraocular Pressure (IOP) at 1 Hour After Nd-YAG Posterior Capsulotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Intraocular Pressure (IOP) at 3 Hours After Nd-YAG Posterior Capsulotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Intraocular Pressure (IOP) at 24 Hours After Nd-YAG Posterior Capsulotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Intraocular Pressure (IOP) at 1 Week After Nd-YAG Posterior Capsulotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Device Success During Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Emotional Stress Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Histological clearance of basal cell carcinoma lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in recruiting and establishing an observational cohort
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) or maximally administered dose (MAD) for ABBV-399
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination half life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects experiencing treatment related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Preliminary anti-tumor activity using Objective Response based on RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of subjects experiencing dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Clinically Significant Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Clinical Disease Severity (CDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Behavioral Symptom Severity (NPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Lactate Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Arterial Blood Pressure ≤ 40 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients changing treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of 10-year ASCVD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Gross Motor Function Classification System - Metachromatic Leukodystrophy (GMFC-MLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral neuropathy grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of major adverse cardiovascular events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average daytime SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Sleep Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Movement of midurethra, bladder neck, cervix and rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of plasma benzoic acid and hippuric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of mastitis
Endpoint domain: Adverse events/effects
Primary endpoint: Mesh Bulging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and Tolerability of Topical Cidofovir
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in central retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with the length of stay in the hospital
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes Body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes Body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes Physical Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pure-tone threshold average (dB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing in Noise Test (signal-to-noise ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep quality for children
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: sleep quality for parents
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Haemostatic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Glycated haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VEGF blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IL-8 blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Plasma HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in CD4+ and CD8+ T-lymphocyte Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time spent searching for sponges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost of time spent searching for sponges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time spent using radiography to rule out the presence of a retained sponge
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC(0-inf) ratio, new tablet vs. capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) ratio, fed state vs. fasted state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax ratio, new tablet vs. capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax ratio, fed state vs. fasted state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with serum liver biochemistry abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 year cumulative incidence of relapse
Endpoint domain: Mortality/survival
Primary endpoint: 2 year cumulative incidence of relapse
Endpoint domain: Mortality/survival
Primary endpoint: Communication Quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Interpretation Quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnosis Comprehension
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Heart rate-corrected QT interval (QTc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose (MTD) of cisplatin
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy as Defined by the Frequency and Severity of Treated Biopsy Proven Acute Rejection (tBPAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Shifts in the subgingival microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of contracting clinical Ebola Virus Disease
Endpoint domain: Mortality/survival
Primary endpoint: Mortality from Ebola Virus Disease
Endpoint domain: Mortality/survival
Primary endpoint: change on pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech in noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemotherapy-induced Peripheral Neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Chemotherapy-induced Neuropathic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardio-pulmonary exercise test measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Appearance of neuropathy secondary to taxanes (CTCAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Appearance of neuropathy secondary to taxanes (TNSc)
Endpoint domain: Adverse events/effects
Primary endpoint: PATET ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes